Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.
Lombardi A, Villa S, Colaneri M, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F, Bassetti M, Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A; “COVID 19 NETWORK”. Lombardi A, et al. Among authors: azzara c. J Infect Public Health. 2024 Mar;17(3):467-473. doi: 10.1016/j.jiph.2023.12.026. Epub 2024 Jan 17. J Infect Public Health. 2024. PMID: 38262085 Free article.
Perfusion fluid-related infections in liver transplant recipients: A 5-year, single-center, retrospective study.
Lombardi A, Renisi G, Dondossola D, Palomba E, Del Prete L, Viero G, Zefelippo A, Azzarà C, Maccaro A, Perali C, Alagna L, Franchi E, Muscatello A, Gori A, Grasselli G, Donato MF, Matinato C, Caccamo L, Antonelli B, Bandera A. Lombardi A, et al. Among authors: azzara c. Transpl Infect Dis. 2023 Oct;25(5):e14130. doi: 10.1111/tid.14130. Epub 2023 Aug 21. Transpl Infect Dis. 2023. PMID: 37605507 Free article.
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, Tonizzo A, Fava M, Valzano AG, Morlacchi LC, Donato MF, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A. Lombardi A, et al. Among authors: azzara c. Biomedicines. 2023 May 26;11(6):1540. doi: 10.3390/biomedicines11061540. Biomedicines. 2023. PMID: 37371635 Free PMC article.